THE DEAL, AT A GLANCE
From the announcementMatisse
01What happenedMatisse raised $14M Series A, announced 2026-09-17From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Why it mattersMatisse is a clinical-stage sepsis drug-development financing thesis centered on using a EUR 14m Series A to advance isupartob sodium into a Phase II sepsis trial.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Matisse · Financing Record
Explore source-linked visual explanations for Matisse. Unsupported claims are withheld while source review continues.
Record 12556 · Recorded date: 2026-09-17
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →